Venex (diosmin) News - LARVOL Sigma

|||||||||| Venclexta (venetoclax) / Roche, AbbVie
Integrating Computational Cytomorphological Analysis of Bone Marrow Smears and Clinical Data for Predicting Response to Venetoclax and Hypomethylating Agents in AML (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_2783;
P2
Recent developments in computer vision permit reliable quantitative analysis of BM morphology and add a novel data modality to predictive modeling. Future work will focus on further exploring quantitative cytomorphology and linking it with other modalities and predictive assays.

|||||||||| Venclexta (venetoclax) / Roche, AbbVie, Venex (diosmin) / Elder Pharma
Preclinical, Journal: Ex Vivo Venetoclax Sensitivity Predicts Clinical Response in Acute Myeloid Leukemia in the Prospective VenEx Trial. (Pubmed Central) - Oct 2, 2024
P2
In univariate and multivariate analysis, ex vivo venetoclax sensitivity was the strongest predictor for a favorable treatment response and survival. The VenEx trial demonstrates the feasibility of integrating ex vivo drug testing into clinical practice to identify AML patients, particularly in the R/R setting, who benefit from venetoclax.

|||||||||| Venex (diosmin) / Elder Pharma
Journal: Complications of cyanoacrylate adhesive closure therapy in chronic venous insufficiency: A single center, single-surgeon study. (Pubmed Central) - Jul 20, 2023
Although CAC therapy is a reliable method, its complications should not be ignored. Its use by experienced surgeons reduces the risk of complications.

|||||||||| Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute
CAPILLARY BLOOD SAMPLING ALLOWS FEASIBLE METHOD FOR VENETOCLAX CONCENTRATION MEASUREMENT IN AN ACADEMIC MULTICENTER CLINICAL TRIAL CONTEXT (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_2182;
P2
In the whole population, median capillary blood C min was 720 (58-12600) ng/L in C1d15 and 846 (134-9790) ng/L in C2d15. There was no significant correlation between age (R 2 0,017, p = 0.115) or weight (R 2 0,003, p = 0.486) and C min on d15.

|||||||||| Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute
BCL-2/BCL-XL INHIBITION INDUCES APOPTOSIS AND CIRCUMVENTS VENETOCLAX RESISTANCE IN TP53-MUTATED ACUTE MYELOID LEUKEMIA (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1845;
P2
In contrast, our BH3 mimetic drug screening results demonstrated that the dual inhibition of BCL-2 and BCL-XL by navitoclax is capable of inducing apoptosis in myeloid blast cells regardless of TP53 mutation status. However, larger patient cohorts and more extensive functional analysis of the anti/pro-apoptotic dependencies in this patient group is warranted.

|||||||||| Venclexta (venetoclax) / Roche, AbbVie
Preclinical, Journal, IO biomarker: Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia. (Pubmed Central) - Dec 16, 2022
P2
001). T his analysis illustrates the feasibility of integrating drug-response profiling into clinical practice and demonstrates excellent predictivity.

|||||||||| Venclexta (venetoclax) / Roche, AbbVie
Ex Vivo Venetoclax Sensitivity Testing Predicts Response and Overall Survival in De Novo and s/R/R AML Patients Treated with Azacitidine and Venetoclax (ENMCC - 295-296) - Nov 4, 2022 - Abstract #ASH2022ASH_5220;
P2
Leukemic blast-specific ex vivo Ven-sensitivity showed a high correlation with treatment responses, and univariate analysis showed Ven-sensitivity to be the best predictor for treatment response. Further, ex vivo Ven-sensitivity predicted longer OS – and importantly, this was also observed in R/R/sAML pts, suggesting the method’s usefulness in selecting pts for Ven-Aza therapy.

|||||||||| Venclexta (venetoclax) / Roche, AbbVie
Ex Vivo Drug Sensitivity Testing to Predict Response to Venetoclax + Azacitidine in Acute Myeloid Leukemia: Interim Results of the Prospective Multicenter Phase II Venex Trial (GWCC - Sidney Marcus Auditorium, Level 4) - Nov 5, 2021 - Abstract #ASH2021ASH_1534;
P2
Notably, experimental conditions had considerable influence on the predictive value of ex vivo Ven sensitivity; thus, between-trial standardization is crucial. The ongoing VenEx trial will validate these findings in the second part of the trial (60 pts) where ex vivo Ven sensitivity guides therapy in pts with R/R or sAML.

|||||||||| Venex (diosmin) / Elder Pharma
Clinical, Journal: Use of Haddenham Venex armsleeve for lymphoedema management in clinical practice. (Pubmed Central) - Mar 13, 2020
This article examines how, following recent improvements to the comfort and overall fit of the Haddenham Venex lymphoedema sleeve, patient feedback informed the implementation of further modifications, and how gaining feedback from patients has empowered them to manage and monitor their own condition. By taking ownership for their own care, long-term control of the condition is improved and self-management is enhanced.



	Diseases Companies Products Productz Mechanisms of Action Sites